This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McLACHLAN, R. I. Articles by SOULES, M. R. Search for Related Content PubMed PubMed Citation Articles by McLACHLAN, R. I. Articles by SOULES, M. R.

The Importance of Luteinizing Hormone in the Control of Inhibin and Progesterone Secretion by the Human Corpus Luteum^*

ROBERT I. McLACHLAN, NANCY L. COHEN, WYLIE W. VALE, JEAN E. RIVIER, HENRY G. BURGER, WILLIAM J. BREMNER and MICHAEL R. SOULES

Departments of Medicine (R.I.M., W.J.B.) and Obstetrics and Gynecology (N.L.C., M.R.S.), University Washington Seattle, Washington 98195
The Veterans Administration Medical Center (W.J.B.) Seattle, Washington 98195
The Peptide Biology Laboratory, The Salk Institute (W. W. V., J.E.R.) La Jolla, California 92037
The Medical Research Centre, Prince Henry's Hospital Campus, Monash Medical Centre (H.G.B.) Melbourne, Australia 3004

Address requests for reprints to: Michael R. Soules, M.D., Department of Obstetrics and Gynecology, RH-20, University of Washington, Seattle, Washington 98195.

Serum inhibin levels rise markedly during the luteal phase of the human menstrual cycle and are closely correlated with serum progesterone (P) levels, suggesting that the corpus luteum (CL) secretes inhibin. While FSH is the major regulator of inhibin secretion by the granulosa cells, the control of CL inhibin secretion is unclear. We hypothesized that, like P, CL inhibin secretion would be LH dependent. To examine this possibility, normal women were given the GnRH antagonist [Ac-D₂Nal¹, D₄CL Phe², D₃Pal₃, Arg₅, DGIU₆ (AA), DAla¹⁰]GnRH (Nal-Glu antagonist) for 3 consecutive days commencing on day 6–8 of the luteal phase. The daily doses were 2.5 (n = 3), 10 (n = 4), and 25 Mg/kg (n = 5), sc. Serum LH levels fell 2 h after injection, and the fall was maximal (70–74%) at 6 h; the degree of suppression was not dose dependent. The duration of suppression was dose related, being less than 12 h, between 12, and 24 h, and more than 24 h for the 2.5, 10, and 25 µg/kg doses, respectively. Serum FSH levels declined by 22–43%, but the effect was not dose related. Serum P levels fell by 42–45% 8 h after each dose of antagonist. They returned to baseline 24 h after the 2.5 µg/kg dose, but after both the 10 and 25 µg/kg doses serum P levels continued to fall, and menstrual bleeding commenced within 48–72 h after the first antagonist injection. Serum inhibin levels were not altered relative to normal cycles by the 2.5 µg/kg dose, but fell by 48% and 58%, and 62% and 73% respectively, 48 and 72 h after the 10 and 25 µg/kg doses, respectively. Serum P and inhibin levels correlated closely in all women. To examine the relative roles of FSH and LH in the control of CL function, Nal-Glu antagonist (25 µg/kg, sc) was administered at 0 and 24 h commencing on day 6–8 of the luteal phase, in combination with either human menopausal gonadotropin (hMG; 150 IU, im, every 12 h) or hCG (1500 IU, im, once), both commencing at 0 h. hMG administration led to a rapid (by 2 h) and marked (3- to 9-fold) rise in serum FSH levels, whereas serum LH remained low, similar to antagonist alone treatment cycles. Serum P levels fell similarly after antagonist with or without hMG administration, as did serum inhibin and estradiol (E₂), except at 48 h when serum E₂ was significantly higher than during antagonist treatment alone. hCG administration led to a 2- to 8-fold elevation in serum LH-like immunoactivity along with modest increases in serum P (+75%), E₂ (+37%), and inhibin (+60%) levels.

We conclude that 1) the Nal-Glu antagonist is a potent inhibitor of gonadotropin secretion, and the duration of its effect is dose related; 2) under the regimen employed, a threshold dose for the induction of luteolysis exists between 2.5–10 µg/kg; 3) the duration of gonadotropin suppression required to induce luteolysis is between 12–24 h on 3 consecutive days; 4) inhibin and P secretion by the CL are coupled during alterations in gonadotropin levels; 5) coadministration of the Nal-Glu antagonist with hMG failed to maintain CL function; and 6) hCG administration maintained CL P and inhibin secretion after antagonist injection, indicating that these hormones are predominantly under LH control.

^* This work was supported by NIH Grants R01-HD-18967 (to M.R.S.) and P50-HD-12629 (to W.J.B.), Clinical Research Center Grant RR-37, and the V.A.

Neil Hamilton Fairley Fellow from the Australian National Health and Medical Research Council.

Received November 29, 1988.

This article has been cited by other articles:

				W. S. Dhillo, O. B. Chaudhri, E. L. Thompson, K. G. Murphy, M. Patterson, R. Ramachandran, G. K. Nijher, V. Amber, A. Kokkinos, M. Donaldson, et al. Kisspeptin-54 Stimulates Gonadotropin Release Most Potently during the Preovulatory Phase of the Menstrual Cycle in Women J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3958 - 3966. [Abstract] [Full Text] [PDF]

				E. Xiao, L. Xia-Zhang, and M. Ferin Inadequate Luteal Function Is the Initial Clinical Cyclic Defect in a 12-Day Stress Model that Includes a Psychogenic Component in the Rhesus Monkey J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2232 - 2237. [Abstract] [Full Text] [PDF]

				B. E. Friden, E. Runesson, M. Hahlin, and M. Brannstrom Evidence for nitric oxide acting as a luteolytic factor in the human corpus luteum Mol. Hum. Reprod., May 1, 2000; 6(5): 397 - 403. [Abstract] [Full Text] [PDF]

				S. B. Seminara, M. Beranova, L. M. B. Oliveira, K. A. Martin, W. F. Crowley Jr., and J. E. Hall Successful Use of Pulsatile Gonadotropin-Releasing Hormone (GnRH) for Ovulation Induction and Pregnancy in a Patient with GnRH Receptor Mutations J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 556 - 562. [Abstract] [Full Text]

				C. K. Welt, J. M. Adams, P. M. Sluss, and J. E. Hall Inhibin A and Inhibin B Responses to Gonadotropin Withdrawal Depends on Stage of Follicle Development J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2163 - 2169. [Abstract] [Full Text]

				J. A. McCracken, E. E. Custer, and J. C. Lamsa Luteolysis: A Neuroendocrine-Mediated Event Physiol Rev, April 1, 1999; 79(2): 263 - 323. [Abstract] [Full Text] [PDF]

				F. J. Hayes, J. E. Hall, P. A. Boepple, and W. F. Crowley Jr. Differential Control of Gonadotropin Secretion in the Human: Endocrine Role of Inhibin J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1835 - 1841. [Full Text]